Intelligence for people who need to know what changed before everyone else.

FDA Accepts BLA761147 for PEGFILGRASTIM-PCCG by Accord Biopharma

American Regent Issues Nationwide Recall of Adequan® Canine and I.M. Lots

Lilly's olomorasib receives FDA Breakthrough Therapy designation for advanced pancreatic cancer

FDA Grants Approval for Vasopressin Application ANDA212068 by Sandoz

Deucravacitinib Shows Promise in Treating Psoriasis with Eczematous Features

Gene Therapy for Sickle Cell Disease Shows Promising Safety and Efficacy in 36 Patients

FDA Approves JAKAFI XR (Ruxolitinib Phosphate) Submission by Incyte

FDA Accepts NDA for Trabectedin by Apotex

FDA Accepts NDA for Vepdegestrant by Arvinas Operations

FDA Approves Glycerol Phenylbutyrate Application by Lupin

FDA Approves Pregabalin Application ANDA219593 by Unichem

FDA Approves Sitagliptin and Metformin Hydrochloride Combination

FDA Approves Lutetium Lu 177 VIPIVOTIDE for Metastatic Prostate Cancer

Resmed Issues Correction for Astral Ventilator Due to Electrical Component Failure

FDA Approves Supplement for VEKLURY (Remdesivir) by Gilead Sciences

FDA Approves QLONILIK (Clonidine Hydrochloride) NDA221094

Study on Multivirus CTL for Viral Infections Post Allogeneic SCT Shows Promise

FDA Grants Approval for Sugammadex Sodium (ANDA218814) by SteriScience

Teva's Sugammadex Sodium Receives FDA Approval Status

FDA Grants Approval for Sugammadex Sodium ANDA219448 by Fresenius Kabi

Phase II/III Trial of Atezolizumab with Chemotherapy for Advanced Neuroendocrine Carcinomas

Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval

Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311)

FDA Approves Sugammadex Sodium for Gland Pharma

Selinexor and Radiation Therapy Trial for DIPG and HGG Shows Promise

Mosunetuzumab shows promise in B-cell NHL beyond follicular lymphoma

CAFs Enhance Adenosine Production in NSCLC, Impeding T Cell Response

FDA Grants Approval for Sugammadex Sodium under ANDA214368

Datroway Approved in EU for Metastatic TNBC as First TROP2-Directed Therapy

Cipla's Lenalidomide ANDA210435 Receives Abbreviated Approval from FDA

FDA Grants Priority Review for NUPLAZID Supplement NDA210793

HPV Vaccine Hesitancy Among Female Students in China Increases Despite Improved Knowledge

CHMP recommends EU approval of Roche’s Susvimo for nAMD treatment

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy

FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment

FDA Approves Veklury as First Treatment for COVID-19

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial

Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma

Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis

FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer

Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer